Article

Lung

, Volume 190, Issue 3, pp 251-262

Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery

  • Lauren WillisAffiliated withDepartment of Pharmaceutical Sciences-Drug Development Division, College of Pharmacy, University of Kentucky
  • , Don HayesJr.Affiliated withDepartments of Pediatrics and Internal Medicine, The Ohio State University College of Medicine, and Lung and Heart-Lung Transplant Programs, Nationwide Children’s Hospital
  • , Heidi M. MansourAffiliated withDepartment of Pharmaceutical Sciences-Drug Development Division, College of Pharmacy, University of KentuckyCenter of Membrane Sciences, University of Kentucky Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Therapeutic liposomal powders (i.e., lipospheres and proliposomes) for dry powder inhalation aerosol delivery, formulated with phospholipids similar to endogenous lung surfactant, offer unique opportunities in pulmonary nanomedicine while offering controlled release and enhanced stability. Many pulmonary diseases such as lung cancer, tuberculosis (TB), cystic fibrosis (CF), bacterial and fungal lung infections, asthma, and chronic obstructive pulmonary disease (COPD) could greatly benefit from this type of pulmonary nanomedicine approach that can be delivered in a targeted manner by dry powder inhalers (DPIs). These delivery systems may require smaller doses for efficacy, exhibit reduced toxicity, fewer side effects, controlled drug release over a prolonged time period, and increased formulation stability as inhaled powders. This state-of-the-art review presents these novel aspects in depth.

Keywords

Pulmonary nanomedicine Asthma Chronic obstructive pulmonary disease Cystic fibrosis Tuberculosis Lung cancer